Browse > Article
http://dx.doi.org/10.4333/KPS.2011.41.6.371

Solid State of Tulobuterol : Characterization, Dissolution, Transformation  

Do, Eui-Seon (Research Laboratory, Dong-A Pharmaceutical Co., Ltd.)
Sohn, Young-Taek (College of Pharmacy, Duksung Women's University)
Publication Information
Journal of Pharmaceutical Investigation / v.41, no.6, 2011 , pp. 371-376 More about this Journal
Abstract
The objective of this work was to investigate the existence of new crystal forms of tulobuterol which is used to prevent morning asthma attacks by ${\beta}_2$ agonist and the transformation of crystal forms. Three crystal forms of tulobuterol have been isolated by recrystallization and Form 2 was transformed to Form 4 at 52% RH and 95% RH and these four crystal forms are characterized by differential scanning calorimetry (DSC), powder X-ray diffractometry (PXRD) and thermogravimetric analysis (TG). The DSC and PXRD patterns of four crystal forms of tulobuterol were different respectively. The dissolution patterns of these three crystal forms of tulobuterol were studied and they showed significant differences in the dissolution rate. After storage of 2 months at 0% RH (silica gel, $20^{\circ}C$), 52% RH (saturated solution of $Na_2Cr_2O_7{\cdot}2H_2O/20^{\circ}C$) and 95% RH (saturated solution of $Na_2HPO_4/20^{\circ}C$), Form 1 and Form 3 were not transformed. But Form 2 was transformed to Form 4 at 52% RH and 95% RH.
Keywords
Tulobuterol; Polymorphism; Crystal form; DSC; PXRD; Dissolution;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
연도 인용수 순위
1 Caira, M.R., Bourne, S.A., and Oliver, C.L., 2004. Thermal and structural characterization of two polymorphs of the bron-chodilator tulobuterol. J. Thermal. Anal. Cal., 77, 597-605.   DOI
2 Campeta, A.M., Chekal, B.P., Abramov, Y.A., Meenan, P.A., Henson, M.J., Shi, B., Singer, R.A., Horspool, K.R., 2010. Development of a targeted polymorph screening approach for a complex polymorphic and highly solvating API. J. Pharm. Sci., 99, 3874-3886.
3 Giron, D., 1995. Thermal analysis and calorimetric methods in the characterization of polymorphs and solvates. Thermochim. Acta, 248, 1-59.   DOI
4 Haleblian, J.K., McCrone, W.C., 1969. Pharmaceutical applications of polymorphism. J. Pharm. Sci., 58, 911-929.   DOI
5 Haleblian, J.K., 1975. Characterization of habits and crystalline modification of solids and their pharmaceutical applications. J. Pharm. Sci., 64, 1269-1288.   DOI
6 Hüttenrauch, R., 2008. Fundamentals of pharmaceutics. Acta Pharm. Technol., 34, 1-10.
7 Lee, E.A., Sohn, Y.T., 2008. Crystal forms of a capsaicin derivative analgesic DA-5018. J. Therm. Anal. Cal., 93, 871-874.   DOI
8 Opalchenova, G. and Kalinkova, G.N., 1997. Evaluation of a new polymorph azlocillin sodium by its antibacterial activity. Int. J. Pharm., 153, 263-265.   DOI
9 Sohn, Y.T., 2007. Crystal forms of an angiotensin II receptor antagonist BR-A657. J. Therm. Anal. Cal., 89, 799-802.   DOI
10 Song, H.O. and Sohn, Y.T., 2010. Crystal forms of SK-3530. Arch. Pharm. Res., 12, 2033-2036.
11 Yamamura, S., Momose, Y., 2001. Quantitative analysis of crystalline pharmaceuticals in powders and tablets by a pattern-fitting procedure using X-ray powder diffraction data. Int. J. Pharm., 212, 203-212.   DOI
12 Bachet, B., 1997. X-ray characterization of the triclinic polymorph of carbamazepine. J. Pharm. Sci. 86, 1062-1065.   DOI